Álvarez M, Castro RL, Gutiérrez DR, Labrada A, Enríquez I, Ronquillo M, Rodríguez J

Language: Spanish
References: 21
Page: 13-18
PDF size: 162.54 Kb.

ABSTRACT

Allergen-specific immunotherapy consists of administering gradually increasing doses of the allergen, to which the patient is sensitized, aiming at achieving tolerance to it and decreasing clinical symptoms. The sublingual immunotherapy (SLIT) was introduced as an alternative to subcutaneous route. The objective was to assess the safety of sublingual standardized vaccines of three domestic mite species (VALERGEN, Cuba) and its adverse events in allergic patients from the Calixto García University Hospital in Havana, as well as the frequency of the vaccine prescription. A descriptive and cross sectional study design included 130 patients with treatment of SLIT with VALERGEN (BIOCEN, Cuba), who attended the Allergy Service in the period from January to September 2010. Age distribution: mean 19.6 years (range 1-75), 40.7% was younger than 18 years. The multiallergen vaccine was the most used (63.8%). The most common allergen was D. pteronyssinus followed by B. tropicalis. 71.55% of administered allergens vaccines were in maintenance phase. We found 4 adverse events (3.1% of patients), all local, mild, and not requiring treatment or change of dosing schedule. The VALERGEN vaccines by sublingual route were shown to be safe and well tolerated in Cuban allergic patients.

REFERENCES

1. 1. Bousquet J, Lockey R, Malling HJ. WHO position paper Allergen immunotherapy: therapeutic vaccines for allergic diseases. J Allergy Clin Immunol 1998;102:558-62.

2. Rodríguez SO. Inmunoterapia sublingual en rinitis alérgica y asma en niños de dos a cinco años sensibilizados con ácaros. Revista Alergia México 2008;55(2):71-5.

3. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica WG. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999;54:1110-3.

4. Gidaro GB, Marcucci F, Sensi L, Incorvaia C, Frati F, Ciprandi G. The safety of sublingual-swallow immunotherapy: an analysis of published studies. Clin Exp Allergy 2005;35:565- 71.

5. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza AY, et al. Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. Chest 2008;133:599- 609.

6. Ulrich W, Tabar A, Kuna P, Halken S, Montagut A, Beaumont O, le Gall M. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. The Journal of Allergy and Clinical Immunology 2009;123(1):160-6.

7. Passalacqua G, Lombardi C, Canonica GW. Sublingual Immunotherapy: An Update. Current Opinion in Allergy & Clinical Immunology 2004;4(1):31-6.

8. Canonica GW, Bousquet J, Casale T, Lockey R, Baena-Cagnani CE, Pawankar R, et al. Sub-Lingual Immunotherapy. World Allergy Organization. Position Paper World Allergy Organization Journal: 2009; 2(11):233-81.

9. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317- 24.

10. Gómez VJ, Flores SG, Orea SM, López TJ, Jiménez SN. Inocuidad y eficacia de la inmunoterapia sublingual específica en pacientes con asma y alergia a Dermatophagoides pteronyssinus. Revista Alergia México 2005;52(6):231-6.

11. Passalacqua G, Guerra L, Fumagalli F, Compatali E, Canonica W. An Update of Sublingual Immunotherapy. Allergy Clin Immunol Int J World Allergy Org 2005;17(5):181-5.

12. De Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2011;64:961-7.

13. Dunsky EH, Goldstein MF, Dvorin DJ, Belecanech GA. Anaphylaxis to sublingual immunotherapy. Allergy 2006; 61: 1235-1244.

14. Eifan AO, Keles S, Bahceciler NN, Barlan IB. Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007;62 (5):567–8.

15. Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236-7.

16. Pérez PM, García DA, Sabina DA, Vega GM, Macías CV. Sensibilización a diferentes tipos de ácaros en pacientes adultos. Rev Cubana Med 2002;41(2):75-8.

17. Castro Almarales RL, González León M, Labrada Rosado A, Navarro Viltre BI, Álvarez Castelló M, García Gómez I. Sensibilización a Dermatophagoides pteronyssinus, Dermatophagoides siboney y Blomia tropicalis en niños de tres consultorios. Rev Cubana Med Gen Integr 2005;21(3-4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 21252005000300022&lng=es.

18. Sánchez-Borges M, Capriles-Hulett A, Malka S. Inhalant allergens clinically significant in Latin America. Allergy Clin Immunol Int: J World Allergy Org 2004;16:28-32.

19. Platts-Mills TAE, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: Report of the Third International Workshop. J Allergy Clin Immunol 1997;100(6):1-24.

20. Castro ARL, Álvarez CM, Ronquillo DM, Rodríguez CJS, García GI, González LM, et al. Sensibilización a tres especies de ácaros en pacientes alérgicos de la zona costera de la ciudad de La Habana. Rev Alerg Mex 2009;56(2):31-5.

21. Campbell D S. Sublingual immunotherapy for children: Are we there yet? Defining its role in clinical practice. Paediatric Respiratory Reviews 2009;10(2):69-74.